Spero Therapeutics, Inc.

Listed Company

SPROCIK 0001701108NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$66.80M

Net Income

$8.60M

Total Assets

$68.92M

Equity

$59.02M

Shares Out

57.89M

Op. Cash Flow

$-12.62M

Business

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing treatments for rare diseases and multi-drug resistant bacterial infections. Its main offerings are investigational antibiotics and therapeutic candidates, including tebipenem HBr, SPR206 and SPR720, advanced through clinical trials. The company organizes operations around clinical development programs, intellectual property management and strategic collaborations and licensing arrangements. It advances programs globally through partnerships and licensees (including GSK, Pfizer, Everest and Meiji) and distributes via hospital and community healthcare channels and regulated clinical trial networks.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Grant revenue	7	21	7	5	15
Collaboration revenue - related party	47	27	96	46	—
Collaboration revenue	13	371,000	933,000	3	3
Total revenues	67	48	104	54	18
Research and development	38	97	51	48	65
General and administrative	21	24	26	36	42
Impairment of long-term asset	587,000	0	5	635,000	—
Restructuring	258,000	877,000	0	12	0
Total operating expenses	60	121	82	96	106
Income (loss) from operations	6	−73	21	−42	−88
Interest income	3	5	4	1	346,000
Other income (expense), net	7,000	60,000	−14,000	−55,000	−395,000
Total other income, net	3	5	4	−4	−2
Net income (loss) before income taxes	9	−69	25	−46	—
Income tax expense	−261,000	0	−3	0	—
Net income (loss) and comprehensive income (loss)	9	−69	23	−46	−90
Net income (loss) per share attributable to common stockholders, basic	0.15	−1.27	0.43	−1.23	−2.91
Net income (loss) per share attributable to common stockholders, diluted	0.15	−1.27	0.43	−1.23	−2.91
Weighted average common shares outstanding, basic:	56	54	53	38	31
Weighted average common shares outstanding, diluted:	59	54	53	38	31

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-09-30	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	40	—	53	76	109
Collaboration receivable, current - related party	25	—	49	49	0
Other receivables	28,000	—	3	2	1
Prepaid expenses and other current assets	2	—	2	4	3
Total current assets	67	—	107	131	114
Operating lease right-of-use assets	1	2	3	4	5
Other assets	153,000	—	153,000	435,000	6
Total assets	69	—	111	182	125
Accounts payable	693,000	—	7	1	617,000
Accrued expenses and other current liabilities	6	—	18	7	9
Operating lease liabilities	2	—	2	2	2
Income taxes payable	383,000	—	174,000	387,000	0
Deferred Revenue, Current	0	—	368,000	2	4
Deferred revenue, current - related party	258,000	—	22	25	6
Total current liabilities	9	—	49	37	22
Non-current operating lease liabilities	939,000	—	3	4	5
Deferred revenue, non-current	0	—	12	11	10
Deferred revenue, non-current - related party	0	—	576,000	24	12
Other long-term liabilities	91,000	—	0	87,000	96,000
Total liabilities	10	—	64	75	49
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and 2023	0	—	0	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2024 and 2023; 54,593,527 shares issued and outstanding as of December 31, 2024 and 52,999,680 shares issued and outstanding as of December 31, 2023	56,000	—	55,000	53,000	52,000
Additional paid-in capital	510	—	506	498	490
Accumulated deficit	−451	—	−460	−391	−414
Total stockholders' equity	59	—	46	107	76
Total liabilities and stockholders' equity	69	—	111	182	125

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	0	2,000	367,000	869,000	646,000
Non-cash lease cost	1	1	969,000	678,000	471,000
Share-based compensation	4	8	8	9	9
Collaboration receivable, current and non-current - related party	24	46	−96	0	—
Other receivables	3	−2	−461,000	2	3
Prepaid expenses and other current assets	277,000	2	−799,000	5	−3
Other assets	0	282,000	−1,000	−3,000	−319,000
Accounts payable	−7	6	761,000	−484,000	−53,000
Accrued expenses and other current liabilities	−12	11	−2	−5	2
Deferred revenue	−13	−370,000	−933,000	22	11
Deferred revenue - related party	−22	−26	30	—	—
Other long-term liabilities	91,000	−87,000	−9,000	−42,000	−39,000
Operating lease liabilities	−1	−1	−1	−688,000	−503,000
Income taxes payable	209,000	−213,000	387,000	0	—
Net cash used in operating activities	−13	−23	−33	−8	−64
Net decrease in cash and cash equivalents	−13	−23	−33	−3	27

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro